Loading cancer entity…
Loading cancer entity…
Clinical trials
10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,643)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT01538472 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2014 |
| NCT00589563 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | completed | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00787527 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2014 | clinicaltrials |
| NCT00225173 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | terminated | Phase 2 | 45 | Stanford UniversityOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT01178645 | Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 42 | Seoul National University HospitalOTHER | 1 | Aug 25, 2014 | clinicaltrials |
| NCT01178658 | Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma | unknown | Phase 2 | 42 | Seoul National University HospitalOTHER | 1 | Aug 25, 2014 | clinicaltrials |
| NCT01499303 | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | completed | Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 22, 2014 | clinicaltrials |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | terminated | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00576758 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 175 | Hoffmann-La RocheINDUSTRY | 17 | Aug 19, 2014 | clinicaltrials |
| NCT00691704 | Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | completed | Phase 2 | 18 | Cristina GasparettoOTHER | 1 | Aug 19, 2014 | clinicaltrials |
| NCT00517699 | A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma. | terminated | Phase 2 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 8, 2014 | clinicaltrials |
| NCT00972959 | Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | completed | Phase 2 | 17 | University of AthensOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00002941 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma | completed | Phase 2 | 69 | Children's Oncology GroupNETWORK | 7 | Aug 1, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00948090 | PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients | completed | Phase 2 | 207 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 2 | Jul 31, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT00002590 | Combination Chemotherapy in Treating Children With Lymphoma | completed | Phase 2 | 221 | Children's Oncology GroupNETWORK | 3 | Jul 24, 2014 | clinicaltrials |
| NCT00002621 | Interferon Alfa in Treating Children With HIV-Related Cancer | completed | Phase 2 | 8 | Children's Oncology GroupNETWORK | 4 | Jul 24, 2014 | clinicaltrials |
| NCT00851552 | Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | terminated | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT00586755 | Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma | completed | Phase 2 | 48 | Duke UniversityOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01078922 | Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | terminated | Phase 2 | 11 | Oncology Specialists, S.C.OTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01279707 | Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)(MARALL) | unknown | Phase 1 / Phase 2 | 55 | Queen Mary University of LondonOTHER | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients(MUNIN) | completed | Phase 2 | 59 | GlaxoSmithKlineINDUSTRY | 1 | Jul 11, 2014 | clinicaltrials |
| NCT02114502 | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 11, 2014 | clinicaltrials |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | terminated | Phase 2 | 22 | Centre Leon BerardOTHER | 1 | Jul 10, 2014 | clinicaltrials |
| NCT00586014 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 91 | Duke UniversityOTHER | 0 | Jul 8, 2014 | clinicaltrials |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | terminated | Phase 2 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01354392 | AZD1152 in Diffuse Large B-cell Lymphoma | completed | Phase 1 / Phase 2 | 15 | Oxford University Hospitals NHS TrustOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00669318 | Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jul 1, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT01096342 | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 2 | Jun 18, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00075881 | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00142116 | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 25 | Steven P. Treon, MD, PhDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00365274 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00302757 | Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00306111 | Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma | completed | Phase 2 | 14 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00514137 | Sunitinib in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | terminated | Phase 2 | 7 | Nerviano Medical SciencesINDUSTRY | 2 | May 28, 2014 | clinicaltrials |
| NCT00058019 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Sep 11, 2014source: clinicaltrials